Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 3/20 | 0.38 |
| ▸ | NPY4R | P50391 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | TFPI | P10646 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 3/20 | 0.37 |
| ▸ | CCKBR | P32239 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329426 | 0.95 | TLR2 (0.43) | OPRL1TLR2NPY1RNPY2RNPY4R | |
| SCHEMBL16358960 | 0.93 | TLR2 (0.45) | TLR2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL22930530 | 0.90 | EPHX2 (0.52) | TLR2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL4940275 | 0.90 | EPHX2 (0.52) | TLR2NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29536066 | 0.89 | GNPAT (0.50) | OPRL1QRFPRGNPATNPY1RNPY2R | |
| SCHEMBL14193566 | 0.89 | GNPAT (0.40) | OPRL1QRFPRCXCR4GNPATNPY1R | |
| SCHEMBL14114071 | 0.89 | EPHX2 (0.47) | NPY1RNPY2RNPY4RNPY5REPHX2 | |
| SCHEMBL16553852 | 0.89 | QRFPR (0.40) | OPRL1QRFPRCXCR4GNPATNPY1R | |
| SCHEMBL17440322 | 0.88 | QRFPR (0.42) | OPRL1TLR2QRFPRCXCR4GNPAT | |
| SCHEMBL13319653 | 0.88 | QRFPR (0.42) | OPRL1TLR2QRFPRCXCR4GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
| WO-2008006097-A2 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES LLC (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | OPRL1 3960/4885TLR2 1233/4885QRFPR 4490/4885 |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | OPRL1 3960/4885TLR2 1233/4885QRFPR 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.